3 sectors are rotating · 8 stable
Three of eleven S&P 500 sectors register a clean leadership flip versus the same calendar window one year ago: Health Care, Energy, and Financials — all turning_positive. The standout is Health Care. Relative strength versus SPY swung 12.4 percentage points (from -7.5 a year ago to +4.9 now), the largest rotation in the scan and by far the cleanest flow signature: $4.3B of 10-day net inflow into XLV, with broad participation across VHT and IYH (cap-weighted variants) and even equal-weight biotech XBI accumulating despite a -3.7% spot return. Energy's flip is real but quieter and mostly concentrated in the integrateds — XLE captured +$131M while every other candidate (XOP, OIH, VDE, AMLP) posted negative flow, a quality-over-cyclicality signature. Financials sit on the rotation line: cap-weighted XLF is up only modestly, but KRE absorbed +$2.1B of 10-day net flow — more than two days of average dollar volume — which is the regional bank reflation trade speaking. The most surprising read this week is the silent rotation INTO defensives even though they remain technically classified stable_negative: XLRE relative gap closed from -6.0 to -0.1 (one more month and it flips), and XLU/XLP each held green on Friday's broad-tape selloff. Tech (XLK) is still the absolute leader (+6.25% on the month) but was already winning a year ago, hence stable rather than rotating — and Friday's -6.6% session is the first sign of leadership exhaustion worth tracking.
Health Care
XLVHealth Care was the worst relative performer in this calendar window a year ago (XLV -0.7% vs SPY +6.8%, RS -7.5). The relationship has inverted: XLV +5.7% vs SPY +0.8% on the same window in 2026. Two forces explain the swing. First, after eighteen months of headline overhang — drug pricing reform, GLP-1 dilution fears, biotech funding drought — the sector entered 2026 with valuations near 10-year relative lows, and the Q1/Q2 earnings cycle has largely cleared a low bar. Second, Friday's tech-led drawdown saw XLV print green while XLK lost 6.6%; that's the classic late-cycle signature of capital rotating into earnings stability. Flow confirms: $4.3B net into XLV, broad participation across VHT/IYH, and even equal-weight biotech XBI accumulating despite spot return down 3.7%.